CD274 and gastroesophageal junction adenocarcinoma: RATIONALE-305 study showed that tislelizumab combined with chemotherapy compared with placebo combined chemotherapy as the first-line treatment significantly prolonged the survival of patients with locally advanced unresectable or metastatic G/GEJ adenocarcinoma when in, regardless of patients’ PD-L1 TAP score ≥ 5% or the whole population [38].